Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
A Pfizer cast-off could become the company's first marketed drug.
Meanwhile, investors await key clinical data.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
But BeOne canned its alcestobart deal in May.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
